FI76808C - Foerfarande foer framstaellning av cefuroxim-1-acetoxietylester. - Google Patents
Foerfarande foer framstaellning av cefuroxim-1-acetoxietylester. Download PDFInfo
- Publication number
- FI76808C FI76808C FI843011A FI843011A FI76808C FI 76808 C FI76808 C FI 76808C FI 843011 A FI843011 A FI 843011A FI 843011 A FI843011 A FI 843011A FI 76808 C FI76808 C FI 76808C
- Authority
- FI
- Finland
- Prior art keywords
- weight
- cefuroxime
- minutes
- stirred
- isomer
- Prior art date
Links
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 53
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 238000002425 crystallisation Methods 0.000 claims description 16
- 230000008025 crystallization Effects 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 11
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 10
- 150000002148 esters Chemical group 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000008282 halocarbons Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229960002620 cefuroxime axetil Drugs 0.000 description 26
- 239000000203 mixture Substances 0.000 description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 239000000725 suspension Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012535 impurity Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 229960001668 cefuroxime Drugs 0.000 description 6
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 6
- 229960000534 cefuroxime sodium Drugs 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 239000010410 layer Substances 0.000 description 5
- -1 1-acetoxyethyl group Chemical group 0.000 description 4
- IIASCQBFNHWZBE-UHFFFAOYSA-N 1-bromoethyl acetate Chemical compound CC(Br)OC(C)=O IIASCQBFNHWZBE-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- IKWLIQXIPRUIDU-ZCFIWIBFSA-N (6r)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound OC(=O)C1=CCS[C@@H]2CC(=O)N12 IKWLIQXIPRUIDU-ZCFIWIBFSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
- C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB838320521A GB8320521D0 (en) | 1983-07-29 | 1983-07-29 | Chemical process |
| GB8320521 | 1983-07-29 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI843011A0 FI843011A0 (fi) | 1984-07-27 |
| FI843011L FI843011L (fi) | 1985-01-30 |
| FI76808B FI76808B (fi) | 1988-08-31 |
| FI76808C true FI76808C (fi) | 1988-12-12 |
Family
ID=10546505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI843011A FI76808C (fi) | 1983-07-29 | 1984-07-27 | Foerfarande foer framstaellning av cefuroxim-1-acetoxietylester. |
Country Status (21)
| Country | Link |
|---|---|
| JP (1) | JPH0613526B2 (pt) |
| KR (1) | KR910008377B1 (pt) |
| AT (1) | AT392470B (pt) |
| AU (2) | AU582121B2 (pt) |
| BE (1) | BE900241A (pt) |
| CA (1) | CA1265511A (pt) |
| CH (1) | CH662121A5 (pt) |
| DE (1) | DE3427828A1 (pt) |
| DK (1) | DK165505C (pt) |
| ES (1) | ES534695A0 (pt) |
| FI (1) | FI76808C (pt) |
| FR (1) | FR2549837B1 (pt) |
| GB (2) | GB8320521D0 (pt) |
| IE (1) | IE57726B1 (pt) |
| IL (1) | IL72536A (pt) |
| NL (1) | NL8402372A (pt) |
| NO (1) | NO167292C (pt) |
| NZ (1) | NZ209046A (pt) |
| PT (1) | PT78985B (pt) |
| SE (1) | SE463263B (pt) |
| ZA (1) | ZA845830B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8400024D0 (en) * | 1984-01-03 | 1984-02-08 | Glaxo Group Ltd | Cephalosporin antibiotics |
| GB8524001D0 (en) * | 1985-09-30 | 1985-11-06 | Glaxo Group Ltd | Pharmaceutical composition |
| US5063224A (en) * | 1990-07-09 | 1991-11-05 | Eli Lilly And Company | R-cefuroxime axetil |
| IT1277426B1 (it) * | 1995-08-03 | 1997-11-10 | Acs Dobfar Spa | Forma cristallina biodisponibile del cefuroxima axetil |
| CN1111537C (zh) * | 1997-05-15 | 2003-06-18 | 第一制糖株式会社 | 高纯晶形头孢呋辛1－乙酰氧乙酯的制备方法 |
| KR100228264B1 (ko) * | 1997-08-02 | 1999-11-01 | 김선진 | 결정형 세푸록심 악세틸의 제조방법 |
| CA2209868C (en) * | 1997-08-15 | 2001-08-14 | Bernard Charles Sherman | Pharmaceutical compositions comprising cefuroxime axetil |
| IN186539B (pt) * | 1997-09-29 | 2001-09-29 | Ranbaxy Lab Ltd | |
| PT937727E (pt) * | 1998-02-20 | 2002-07-31 | Fako Ilaclari A S | Processo para a producao de cefuroxima azetil cristalina soluvel |
| IN190849B (pt) | 2000-07-17 | 2003-08-23 | Ranbaxy Lab Ltd | |
| AT411996B (de) | 2000-09-11 | 2004-08-26 | Sandoz Ag | Verfahren zur herstellung von cefuroxim in der form seines n-butylammoniumsalzes |
| ITMI20011763A1 (it) * | 2001-08-10 | 2003-02-10 | Antibioticos Spa | Processo di preparazione di cefuroxime axelite ad elevata purezza |
| ITMI20011925A1 (it) * | 2001-09-14 | 2003-03-14 | Antibioticos Spa | Metodo applicabile su scala industriale per la preparazione di cefuroxime axetile cristallino |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| CN100448879C (zh) * | 2004-07-22 | 2009-01-07 | 北京化工大学 | 一种无定型头孢呋辛酯的制备方法 |
| DE102005019458A1 (de) | 2005-04-25 | 2006-10-26 | Grünenthal GmbH | Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil |
| CN118561870A (zh) * | 2024-05-15 | 2024-08-30 | 广东立国制药有限公司 | 一种制备头孢呋辛酸的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1094545A (en) * | 1976-02-16 | 1981-01-27 | Michael Gregson | Cephalosporin antibiotics |
| GB1571683A (en) * | 1976-02-16 | 1980-07-16 | Glaxo Operations Ltd | Ester derivatives of cefuroxime |
| GB1598568A (en) * | 1977-04-19 | 1981-09-23 | Glaxo Lab Ltd | Esters of(6r,7r)-3-carbamoyloxymethyl-7-((z)-2-(fur-2-yl)-2-methoxyiminoacetamido)-ceph-3-em-4-carboxylic acid |
| JPS577485A (en) * | 1980-06-13 | 1982-01-14 | Takeda Chem Ind Ltd | Cephalosporin |
| YU44680B (en) * | 1982-07-30 | 1990-12-31 | Glaxo Lab Ltd | Process for obtaining very pure amorphous form of cephuroxim axetile |
| GB8400024D0 (en) * | 1984-01-03 | 1984-02-08 | Glaxo Group Ltd | Cephalosporin antibiotics |
-
1983
- 1983-07-29 GB GB838320521A patent/GB8320521D0/en active Pending
-
1984
- 1984-07-27 ZA ZA845830A patent/ZA845830B/xx unknown
- 1984-07-27 KR KR1019840004465A patent/KR910008377B1/ko not_active Expired
- 1984-07-27 CA CA000459929A patent/CA1265511A/en not_active Expired - Fee Related
- 1984-07-27 DK DK366684A patent/DK165505C/da not_active IP Right Cessation
- 1984-07-27 PT PT78985A patent/PT78985B/pt unknown
- 1984-07-27 NL NL8402372A patent/NL8402372A/nl not_active Application Discontinuation
- 1984-07-27 AT AT2444/84A patent/AT392470B/de not_active IP Right Cessation
- 1984-07-27 BE BE0/213398A patent/BE900241A/fr not_active IP Right Cessation
- 1984-07-27 GB GB08419202A patent/GB2145409B/en not_active Expired
- 1984-07-27 IE IE1938/84A patent/IE57726B1/en not_active IP Right Cessation
- 1984-07-27 FI FI843011A patent/FI76808C/fi not_active IP Right Cessation
- 1984-07-27 CH CH3672/84A patent/CH662121A5/de not_active IP Right Cessation
- 1984-07-27 AU AU31256/84A patent/AU582121B2/en not_active Ceased
- 1984-07-27 FR FR8412011A patent/FR2549837B1/fr not_active Expired
- 1984-07-27 SE SE8403897A patent/SE463263B/sv not_active IP Right Cessation
- 1984-07-27 JP JP59155694A patent/JPH0613526B2/ja not_active Expired - Lifetime
- 1984-07-27 ES ES534695A patent/ES534695A0/es active Granted
- 1984-07-27 DE DE19843427828 patent/DE3427828A1/de not_active Ceased
- 1984-07-27 NO NO843055A patent/NO167292C/no not_active IP Right Cessation
- 1984-07-29 IL IL72536A patent/IL72536A/xx not_active IP Right Cessation
- 1984-07-30 NZ NZ209046A patent/NZ209046A/en unknown
-
1989
- 1989-06-16 AU AU36601/89A patent/AU634965B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI76808C (fi) | Foerfarande foer framstaellning av cefuroxim-1-acetoxietylester. | |
| US4562181A (en) | Amorphous form of cefuroxime ester | |
| US4267320A (en) | Cephalosporin antibiotics | |
| GB2145408A (en) | Improvements in or relating to preparing sodium cefuroxime | |
| SU541438A3 (ru) | Способ получени ацилуреидоцефалоспоринов или их солей или эфиров | |
| US4260607A (en) | Cephalosporin esters | |
| FI75168B (fi) | Foerfarande foer framstaellning av natriumcefuroxim eller ett solvat daerav och natriumcefuroximtetrahydrofuransolvat anvaendbart som mellanprodukt vid foerfarandet. | |
| CH628900A5 (fr) | Procede de preparation de thio-oximes derivees de cephalosporines et de penicillines. | |
| EP1228074A4 (en) | PREPARATION OF CEFPODOXIME PROXETIL WITH HIGH PURITY | |
| US5182383A (en) | Stable, crystalline form of a cephalosporin intermediate product | |
| US3522250A (en) | Derivatives of 7-aminocephalosporanic acid | |
| KR100423890B1 (ko) | 세팔로스포린 유도체의 새로운 제조방법 | |
| BE821243A (fr) | Derives de la penicilline | |
| WO2004037832A1 (en) | An improved process for the preparation of cefixime | |
| EP0186586A2 (en) | Cephem compounds and the production thereof | |
| IE49703B1 (en) | Oxa-beta-lactam derivative | |
| KR100402595B1 (ko) | 페니실린 g 페닐에스테르의 개량 제조 방법 | |
| KR830000341B1 (ko) | 세팔로스포린 유도체의 제법 | |
| SU1118289A3 (ru) | Способ получени производных цефалоспорина | |
| DE2436772C2 (de) | Verfahren zur Extraktion von N-blockierten Cephalosporin- oder Penicillinverbindungen aus deren wäßrigen Lösungen | |
| KR950011746B1 (ko) | 3-프로페닐세펨 유도체 | |
| FI72123C (fi) | 7-/d(-)- -(4-etyl-2,3-dioxo-1 -piperazinkarboxiamido)- -(4-hydroxifenyl)acetamido/-3-/5-(1-metyl -1,2,3,4-tetrazolyl)tiometyl/- 3-cefem-4-karboxylsyrans n,n-dimetylacetamidaddukt och foerfarande foer framstaellning av denna. | |
| KR100400498B1 (ko) | 세펨 유도체 또는 그 염의 신규한 제조방법 | |
| EP0122155A2 (en) | Improvements in or relating to naphthylglycyl cephalosporin derivatives | |
| JPH0662636B2 (ja) | セフロキシムの製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: GLAXO GROUP LIMITED |